LANDOS BIOPHARMA INC
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The Company through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need. Its platform discovers small molecule therapeutics for patients with autoimmune diseases that target mechanisms of action, including LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. The Company has identified approximately seven immunometabolic pathways or targets. It is focused on its clinical-stage programs, including omilancor for the treatment of ulcerative colitis (UC), NX-13 for the treatment of UC and LABP-104 for the potential treatment of systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).
Buy US stocks in Australia starting with LABP. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in LABP
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.